Item 2.02. Results of Operations and Financial Condition. On July 9, 2026 ImmuCell Corporation (the "Company") issued a press release announcing a 11.5% increase in product sales in Q2 of 2026 as compared to Q2 of 2025, based on preliminary, unaudited sales results for the quarter ended June 30, 2026.…
ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional mastitis antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item 2.02.
Results of Operations and Financial Condition.
On July 9, 2026 ImmuCell Corporation (the "Company") issued a press release announcing a 11.5% increase in product sales in Q2 of 2026 as compared to Q2 of 2025, based on preliminary, unaudited sales results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information shall not be deemed "filed" for purposed of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, not shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
